Skip to search formSkip to main contentSkip to account menu

177Lu-PSMA-617

Known as: 177Lu-617-prostate-specific membrane antigen ligand 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

DipeptidesHeterocyclic Compounds, 1-Ring

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
Prostate-specific membrane antigen (PSMA) is a cell membrane glycoprotein that is selectively expressed in prostate cells, with… 
2019
2019
Response Prediction of 177Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase
Neuroendocrinelike transdifferentiation of prostate cancer adenocarcinomas correlates with serum levels of chromogranin A (CgA… 
Highly Cited
2018
Highly Cited
2018
177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment
PurposeThe purpose of this study was to evaluate the efficacy and safety of a novel theranostic agent, 177Lu-DKFZ-PSMA-617… 
Review
2018
Review
2018
Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis
Purpose We performed a meta-analysis on the therapeutic effects of prostate-specific membrane antigen (PSMA)–617 labeled with… 
2018
2018
Comparison Between 64Cu‐PSMA‐617 PET/CT and 18F‐Choline PET/CT Imaging in Early Diagnosis of Prostate Cancer Biochemical Recurrence
2018
2018
Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma
In vivo pharmacokinetic analysis of [44Sc]Sc-PSMA-617 was used to determine the normal organ-absorbed doses that may result from… 
Review
2017
Review
2017
Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer
Objective 177Lu-DKFZ-PSMA-617, a urea-based compound, binds to the extracellular domain of prostate-specific membrane antigen… 
2017
2017
Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer
Clinical 177Lu-PSMA-617 radioligand therapy (RLT) is applied in advanced-stage prostate cancer. However, to the best of our… 
Highly Cited
2016
Highly Cited
2016
[177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer].
Radioligand therapy (RLT) using 177Lu labelled inhibitors of the prostate-specific membrane antigen (177Lu-PSMA) is performed in… 
Highly Cited
2016
Highly Cited
2016
64Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies.
AIM The prostate-specific membrane antigen (PSMA) is a cell surface protein, which is overexpressed in nearly all cases of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)